Synergistic retinal UCHL1 dysregulation and synaptic vulnerability reflect Alzheimer’s disease severity

Read full text
Authors: Altan Rentsendorj, Jean‐Philippe Vit, Alexandre Hutton, Yosef Koronyo, Saba Shahin, Edward Robinson, Ernesto Barrón, Anthony Rodriguez, Bhakta Prasad Gaire, Ousman Jallow, Julia Sheyn, Miyah R. Davis
+11 more Alexander V. Ljubimov, Stuart L. Graham, Vivek K. Gupta, Mehdi Mirzaei, Debra Hawes, Keith L Black, Lon S. Schneider, Alfredo A. Sadun, Jesse G. Meyer, Dieu-Trang S. Fuchs, Maya Koronyo‐Hamaoui
Cited by: 0
References: 138

Abstract

Synaptic failure predicts cognitive decline in Alzheimer's disease (AD), yet its impact and molecular drivers in the human retina remain unclear. Leveraging the retina as an accessible central nervous system (CNS) proxy, we integrated spatially resolved histopathology of retinal cross-sections with ultrastructural, proteomic, and biochemical profiling across independent postmortem cohorts spanning normal cognition, mild cognitive impairment due to AD (MCI), and AD dementia. We uncover early, progressive degeneration of excitatory glutamatergic synapses, evidenced by losses of presynaptic vesicular glutamate transporter 1 (VGLUT1) and synaptophysin, and postsynaptic density protein 95 (PSD95) and N-methyl-D-aspartate receptor subunit 2A (NMDAR2A), accompanied by disruption of synaptic ultrastructure. Retinal synaptic loss tightly associates with local accumulation of amyloid-β 42 (Aβ42) and immature tau species, heightened oxidative stress, and upregulation of the Aβ-binding death receptor p75 neurotrophin receptor (p75NTR). Notably, the synapse-enriched deubiquitinase ubiquitin C-terminal hydrolase L1 (UCHL1) is profoundly dysregulated, correlates with synaptic integrity and cognition, and emerges as the strongest retinal predictor of Braak stage and cognitive status in multivariable machine-learning models. Together, these findings position retinal Aβ/p75NTR-mediated UCHL1 imbalance as a proteostasis-synapse mechanistic hub and candidate biomarker reflecting AD severity.

Fields of Study & Subjects

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
5 February 2026
Language
EN
Document type
Preprint